Specific Guidelines and Methods for HTA of Oncology Products (Cancer HTA)

(1) Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria

(2) Division of Public Health Decision Modelling, Health Technology Assessment and Health Economics, **ONCOTYROL** - Center for Personalized Cancer Medicine, Innsbruck, Austria


(3) Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA

(4) Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, **Harvard Medical School**, Boston, MA, USA

HTAi Conference 2011

Acknowledgements

This work was supported by the ONCOTYROL Center for Personalized Cancer Medicine*.



*ONCOTYROL is a K1-COMET Center and funded by the Federal Ministry for Transport, Innovation and Technology (BMVIT) and the Federal Ministry of Economics and Labour/the Federal Ministry of Economy, Family and Youth (BMWA/BMWFJ), the Tyrolean Future Foundation (TZS) and the State of Styria represented by the Styrian Business Promotion Agency (SFG) and supported by UMIT - University for Health Sciences, Medical Informatics and Technology.

Overview



- Background
- Objectives
- Methods
- Results
- Limitations
- Conclusion

Background



Heterogeneous guidelines for procedures and methods in HTA

Variation according to different countries and diseases

Objectives



 Identify guidelines for HTA of oncology products

 Determine characteristics and dissimilarities in relation to HTA guidelines for non-oncology products

Methods



- Systematic search on the homepages of several HTAorganizations in Europe, Australia, North and South America
 - leading and nationally operating agencies incorporated in a stable environment,
 - financed mainly publicly
 - publish either German or English documents
- Documents with guidance on HTA evaluating oncology technologies
- Data extraction with a standardized extraction sheet
- Contact to the agencies where necessary

Results



- Three documents, published by CADTH (CA), NICE (UK) and the German Cancer Society (DE)
- NICE guidance focused on specific conditions for reimbursement for end-of-life treatments,
- CADTH and German Cancer Society dealt with specific challenges using typical HTA framework for cancer drugs

Results II



- Aidelsburger P, Wasem J. Kosten-Nutzen-Bewertungen von onkologischen Therapien. Deutsche Krebsgesellschaft e.V., 2008.
- Raftery J. NICE and the challenge of cancer drugs. BMJ 2009;338(b67):271-271.
- Mittmann N, Evans WK, Rocchi A, Longo CJ, Au H-J-, Husereau D, Leighl N, Isogai P, Krahn M, Peacock S, Marshall D, Coyle D, Malfair Taylor SC, Jacobs P, Oh PI. Addendum to CADTH's Guidelines for the Economic Evaluation of Health Technologies: Specific Guidance for Oncology Products. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH), 2009.

Results III



- Selection of comparators in the assessment of oncology products appears to be complex
- Cross-over study designs can bias the effect estimators of the clinical efficacy results
- The most commonly used clinical outcome measure overall survival (OS) does not capture toxicity
 - a summary measure allowing weighing benefit and harm is needed
- Surrogate outcomes, like progression free survival, must be extrapolated to OS and the type of relationship must be justified

Conclusions



- Cancer specific HTA guidelines identified special challenges in the evaluation of oncology products and partly recommended standards for a reference case
- The included documents differed in their focus
 > recommendations are not comparable

Thank you,

Danke, Obrigada !

<u>contact</u>: imke.schall@umit.at